000132437 001__ 132437
000132437 005__ 20240229105016.0
000132437 0247_ $$2doi$$a10.1007/s00259-017-3854-6
000132437 0247_ $$2pmid$$apmid:29038888
000132437 0247_ $$2ISSN$$a0340-6997
000132437 0247_ $$2ISSN$$a1432-105X
000132437 0247_ $$2ISSN$$a1619-7070
000132437 0247_ $$2ISSN$$a1619-7089
000132437 0247_ $$2altmetric$$aaltmetric:27756213
000132437 037__ $$aDKFZ-2018-00125
000132437 041__ $$aeng
000132437 082__ $$a610
000132437 1001_ $$0P:(DE-He78)c420f6efccb409e1a287be027501a74c$$aFreitag, Martin$$b0$$eFirst author$$udkfz
000132437 245__ $$aSimultaneous whole-body18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study.
000132437 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2018
000132437 3367_ $$2DRIVER$$aarticle
000132437 3367_ $$2DataCite$$aOutput Types/Journal article
000132437 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521456037_12159
000132437 3367_ $$2BibTeX$$aARTICLE
000132437 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132437 3367_ $$00$$2EndNote$$aJournal Article
000132437 520__ $$aThe aim of the present study was to explore the clinical feasibility and reproducibility of a comprehensive whole-body18F-PSMA-1007-PET/MRI protocol for imaging prostate cancer (PC) patients.Eight patients with high-risk biopsy-proven PC underwent a whole-body PET/MRI (3 h p.i.) including a multi-parametric prostate MRI after18F-PSMA-1007-PET/CT (1 h p.i.) which served as reference. Seven patients presented with non-treated PC, whereas one patient presented with biochemical recurrence. SUVmean-quantification was performed using a 3D-isocontour volume-of-interest. Imaging data was consulted for TNM-staging and compared with histopathology. PC was confirmed in 4/7 patients additionally by histopathology after surgery. PET-artifacts, co-registration of pelvic PET/MRI and MRI-data were assessed (PI-RADS 2.0).The examinations were well accepted by patients and comprised 1 h. SUVmean-values between PET/CT (1 h p.i.) and PET/MRI (3 h p.i.) were significantly correlated (p < 0.0001, respectively) and similar to literature of18F-PSMA-1007-PET/CT 1 h vs 3 h p.i. The dominant intraprostatic lesion could be detected in all seven patients in both PET and MRI. T2c, T3a, T3b and T4 features were detected complimentarily by PET and MRI in five patients. PET/MRI demonstrated moderate photopenic PET-artifacts surrounding liver and kidneys representing high-contrast areas, no PET-artifacts were observed for PET/CT. Simultaneous PET-readout during prostate MRI achieved optimal co-registration results.The presented18F-PSMA-1007-PET/MRI protocol combines efficient whole-body assessment with high-resolution co-registered PET/MRI of the prostatic fossa for comprehensive oncological staging of patients with PC.
000132437 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000132437 588__ $$aDataset connected to CrossRef, PubMed,
000132437 7001_ $$aKesch, Claudia$$b1
000132437 7001_ $$0P:(DE-He78)427023ff7e5f28a11e61fce0b4917b57$$aCardinale, Jens$$b2$$udkfz
000132437 7001_ $$aFlechsig, Paul$$b3
000132437 7001_ $$0P:(DE-He78)f0ab09cfecf353f363bab4cc983de95d$$aFloca, Ralf Omar$$b4$$udkfz
000132437 7001_ $$aEiber, Matthias$$b5
000132437 7001_ $$0P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aBonekamp, David$$b6$$udkfz
000132437 7001_ $$aRadtke, Jan P$$b7
000132437 7001_ $$aKratochwil, Clemens$$b8
000132437 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, Klaus$$b9$$udkfz
000132437 7001_ $$aHohenfellner, Markus$$b10
000132437 7001_ $$aStenzinger, Albrecht$$b11
000132437 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b12$$udkfz
000132437 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b13$$udkfz
000132437 7001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik$$b14$$eLast author$$udkfz
000132437 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-017-3854-6$$gVol. 45, no. 3, p. 340 - 347$$n3$$p340 - 347$$tEuropean journal of nuclear medicine and molecular imaging$$v45$$x1619-7089$$y2018
000132437 909CO $$ooai:inrepo02.dkfz.de:132437$$pVDB
000132437 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c420f6efccb409e1a287be027501a74c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132437 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)427023ff7e5f28a11e61fce0b4917b57$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132437 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0ab09cfecf353f363bab4cc983de95d$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132437 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000132437 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000132437 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000132437 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000132437 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000132437 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000132437 9141_ $$y2018
000132437 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132437 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132437 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132437 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000132437 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000132437 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000132437 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132437 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132437 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132437 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132437 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132437 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132437 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000132437 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000132437 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x1
000132437 9201_ $$0I:(DE-He78)E071-20160331$$kE071$$lSoftwareentwicklung für Integrierte Diagnostik und Therapie(SIDT)$$x2
000132437 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x3
000132437 980__ $$ajournal
000132437 980__ $$aVDB
000132437 980__ $$aI:(DE-He78)E010-20160331
000132437 980__ $$aI:(DE-He78)E030-20160331
000132437 980__ $$aI:(DE-He78)E071-20160331
000132437 980__ $$aI:(DE-He78)E060-20160331
000132437 980__ $$aUNRESTRICTED